The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
The National Institute of Allergy and Infectious Diseases has stopped administering an experimental HIV vaccine in the South Africa HVTN 702 clinical trial, after an independent data and safety monitoring board has found that the vaccine is ineffective at preventing HIV infection.
Take a look at the industry headlines from the last 2 months, including the FDA…
In this infographic we take a look at the long-acting formulations for HIV prevention and treatment currently in the clinical pipeline – from Phase I to approval.
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
A clinical trial conducted in sub-Saharan African countries over 3 years, has revealed a candidate vaccine for tackling tuberculosis. The candidate vaccine, M72/AS01E, was reported to be 54% effective at preventing active pulmonary tuberculosis disease.
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and…
Take a look at this month’s industry headlines including US FDA approvals for two drugs – Xenleta™ and Pretomanid – in addition to an EMA decision for Zerbaxa®, partnerships for vaccine development and results on Ebola therapeutics.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
